The role of the mesentery in Crohn's disease: The contributions of nerves, vessels, lymphatics, and fat to the pathogenesis and disease course

Inflammatory Bowel Diseases

Volumn 22, Issue 6, 2016, Pages 1483-1495

  Li, Yi ^a,b   Zhu, Weiming ^a   Zuo, Lugen ^a   Shen, Bo ^b  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

blood vessels; Crohn's disease; lymphatics; mesenteric adipose tissue; mesenteric nerves

Indexed keywords

VASCULOTROPIN A;

AUTONOMIC NERVE; CROHN DISEASE; DISEASE COURSE; EFFERENT NERVE; FAT MASS; HUMAN; LYMPH VESSEL; MESENTERIC FAT; MESENTERIC NERVE; MESENTERY; MESENTERY BLOOD VESSEL; NERVE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SYMPATHETIC NERVE; VAGUS NERVE; INNERVATION; INTRA-ABDOMINAL FAT; LYMPHATIC SYSTEM; PATHOPHYSIOLOGY; VASCULARIZATION;

CROHN DISEASE; HUMANS; INTRA-ABDOMINAL FAT; LYMPHATIC SYSTEM; MESENTERY;

EID: 84970983909     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000791     Document Type: Review

References (214)

1. Crohn BB, Ginzburg L, Oppenheimer GD. Regional ileitis; a pathologic and clinical entity. Am J Med. 1952;13:583-590.
2. Sheehan AL, Warren BF, Gear MW, et al. Fat-wrapping in Crohn?s disease: pathological basis and relevance to surgical practice. Br J Surg. 1992;79:955-958.
3. Weakley FL, Turnbull RB. Recognition of regional ileitis in the operating room. Dis Colon Rectum. 1971;14:17-23.
4. Borley NR, Mortensen NJ, Jewell DP, et al. The relationship between inflammatory and serosal connective tissue changes in ileal Crohn?s disease: evidence for a possible causative link. J Pathol. 2000;190: 196-202.
5. Frayn KN, Karpe F, Fielding BA, et al. Integrative physiology of human adipose tissue. Int J Obes Relat Metab Disord. 2003;27:875-888.
6. Bertin B, Desreumaux P, Dubuquoy L. Obesity, visceral fat and Crohn?s disease. Curr Opin Clin Nutr Metab Care. 2010;13:574-580.
7. Herlinger H, Furth EE, Rubesin SE. Fibrofatty proliferation of the mesentery in Crohn disease. Abdom Imaging. 1998;23:446-448.
8. Crohn BB, Ginzburg L, Oppenheimer GD. Regional ileitis: a pathologic and clinical entity. 1932. Mt Sinai J Med. 2000;67:263-268.
9. Koh DM, Miao Y, Chinn RJ, et al. MR imaging evaluation of the activity of Crohn?s disease. AJR Am J Roentgenol. 2001;177:1325-1332.
10. Chiorean MV, Sandrasegaran K, Saxena R, et al. Correlation of CT enteroclysis with surgical pathology in Crohn?s disease. Am J Gastroenterol. 2007;102:2541-2550.
11. Villanacci V, Bassotti G, Nascimbeni R, et al. Enteric nervous system abnormalities in inflammatory bowel diseases. Neurogastroenterol Motil. 2008;20:1009-1016.
12. Gross KJ, Pothoulakis C. Role of neuropeptides in inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:918-932.
13. Ferrante M, de Hertogh G, Hlavaty T, et al. The value of myenteric plexitis to predict early postoperative Crohn?s disease recurrence. Gastroenterology. 2006;130:1595-1606.
14. Powley TL, Phillips RJ. Musings on the wanderer: what?s new in our understanding of vago-vagal reflexes?. I. morphology and topography of vagal afferents innervating the GI tract. Am J Physiol Gastrointest Liver Physiol. 2002;283:G1217-G1225.
15. Ratcliffe EM, Farrar NR, Fox EA. Development of the vagal innervation of the gut: steering the wandering nerve. Neurogastroenterol Motil. 2011;23:898-911.
16. Berthoud HR, Neuhuber WL. Functional and chemical anatomy of the afferent vagal system. Auton Neurosci. 2000;85:1-17.
17. Browning KN, Travagli RA. Plasticity of vagal brainstem circuits in the control of gastric function. Neurogastroenterol Motil. 2010;22: 1154-1163.
18. Furness JB. The origin and distribution of adrenergic nerve fibres in the guinea-pig colon. Histochemie. 1970;21:295-306.
19. Felten DL, Felten SY, Carlson SL, et al. Noradrenergic and peptidergic innervation of lymphoid tissue. J Immunol. 1985;135:755s-765s.
20. Linden DR. Enhanced excitability of guinea pig inferior mesenteric ganglion neurons during and following recovery from chemical colitis. Am J Physiol Gastrointest Liver Physiol. 2012;303:G1067-G1075.
21. Wojtkiewicz J, Rowniak M, Crayton R, et al. Inflammation-induced changes in the chemical coding pattern of colon-projecting neurons in the inferior mesenteric ganglia of the pig. J Mol Neurosci. 2012;46: 450-458.
22. Tracey KJ. Reflex control of immunity. Nat Rev Immunol. 2009;9: 418-428.
23. Matteoli G, Boeckxstaens GE. The vagal innervation of the gut and immune homeostasis. Gut. 2013;62:1214-1222.
24. O?Mahony C, van der Kleij H, Bienenstock J, et al. Loss of vagal antiinflammatory effect: in vivo visualization and adoptive transfer. Am J Physiol Regul Integr Comp Physiol. 2009;297:R1118-R1126.
25. Ghia JE, Blennerhassett P, Collins SM. Impaired parasympathetic function increases susceptibility to inflammatory bowel disease in a mouse model of depression. J Clin Invest. 2008;118:2209-2218.
26. Ghia JE, Blennerhassett P, Kumar-Ondiveeran H, et al. The vagus nerve: a tonic inhibitory influence associated with inflammatory bowel disease in a murine model. Gastroenterology. 2006;131:1122-1130.
27. Ghia JE, Blennerhassett P, Deng Y, et al. Reactivation of inflammatory bowel disease in a mouse model of depression. Gastroenterology. 2009; 136:2280-2288. e2281-e2284.
28. Straub RH, Stebner K, Harle P, et al. Key role of the sympathetic microenvironment for the interplay of tumour necrosis factor and interleukin 6 in normal but not in inflamed mouse colon mucosa. Gut. 2005; 54:1098-1106.
29. Motagally MA, Neshat S, Lomax AE. Inhibition of sympathetic N-Type voltage-gated Ca2+ current underlies the reduction in norepinephrine release during colitis. Am J Physiol Gastrointest Liver Physiol. 2009; 296:G1077-G1084.
30. Straub RH, Grum F, Strauch U, et al. Anti-inflammatory role of sympathetic nerves in chronic intestinal inflammation. Gut. 2008;57:911-921.
31. Swain MG, Blennerhassett PA, Collins SM. Impaired sympathetic nerve function in the inflamed rat intestine. Gastroenterology. 1991; 100:675-682.
32. Straub RH, Herfarth H, Falk W, et al. Uncoupling of the sympathetic nervous system and the hypothalamic-pituitary-Adrenal axis in inflammatory bowel disease?. J Neuroimmunol. 2002;126:116-125.
33. Geboes K, Collins S. Structural abnormalities of the nervous system in Crohn?s disease and ulcerative colitis. Neurogastroenterol Motil. 1998; 10:189-202.
34. Dvorak AM, Silen W. Differentiation between Crohn?s disease and other inflammatory conditions by electron microscopy. Ann Surg. 1985;201: 53-63.
35. Belai A, Boulos PB, Robson T, et al. Neurochemical coding in the small intestine of patients with Crohn?s disease. Gut. 1997;40:767-774.
36. Magro F, Vieira-Coelho MA, Fraga S, et al. Impaired synthesis or cellular storage of norepinephrine, dopamine, and 5-hydroxytryptamine in human inflammatory bowel disease. Dig Dis Sci. 2002;47:216-224.
37. Penttila O, Kyosola K, Klinge E, et al. Studies of rectal mucosal catecholamines in ulcerative colitis. Ann Clin Res. 1975;7:32-36.
38. Kyosola K, Penttila O, Salaspuro M. Rectal mucosal adrenergic innervation and enterochromaffin cells in ulcerative colitis and irritable colon. Scand J Gastroenterol. 1977;12:363-367.
39. Hollander D. Inflammatory bowel diseases and brain-gut axis. J Physiol Pharmacol. 2003;54(suppl 4):183-190.
40. Bonaz BL, Bernstein CN. Brain-gut interactions in inflammatory bowel disease. Gastroenterology. 2013;144:36-49.
41. Maunder RG. Evidence that stress contributes to inflammatory bowel disease: evaluation, synthesis, and future directions. Inflamm Bowel Dis. 2005;11:600-608.
42. Goodhand JR, Wahed M, Mawdsley JE, et al. Mood disorders in inflammatory bowel disease: relation to diagnosis, disease activity, perceived stress, and other factors. Inflamm Bowel Dis. 2012;18:2301-2309.
43. Targownik LE, Sexton KA, Bernstein MT, et al. The relationship among perceived stress, symptoms, and inflammation in persons with inflammatory bowel disease. Am J Gastroenterol. 2015;110:1001-1012.
44. Camara RJ, Schoepfer AM, Pittet V, et al. Mood and nonmood components of perceived stress and exacerbation of Crohn?s disease. Inflamm Bowel Dis. 2011;17:2358-2365.
45. Graff LA, Walker JR, Clara I, et al. Stress coping, distress, and health perceptions in inflammatory bowel disease and community controls. Am J Gastroenterol. 2009;104:2959-2969.
46. Goodhand JR, Greig FI, Koodun Y, et al. Do antidepressants influence the disease course in inflammatory bowel disease?. A retrospective casematched observational study. Inflamm Bowel Dis. 2012;18:1232-1239.
47. Bonaz B. The cholinergic anti-inflammatory pathway and the gastrointestinal tract. Gastroenterology. 2007;133:1370-1373.
48. Wakefield AJ, Sawyerr AM, Dhillon AP, et al. Pathogenesis of Crohn?s disease: multifocal gastrointestinal infarction. Lancet. 1989;2:1057-1062.
49. Wakefield AJ, Pittilo RM, Sim R, et al. Evidence of persistent measles virus infection in Crohn?s disease. J Med Virol. 1993;39:345-353.
50. Danese S. Role of the vascular and lymphatic endothelium in the pathogenesis of inflammatory bowel disease: brothers in arms?. Gut. 2011; 60:998-1008.
51. Scaldaferri F, Sans M, Vetrano S, et al. Crucial role of the protein C pathway in governing microvascular inflammation in inflammatory bowel disease. J Clin Invest. 2007;117:1951-1960.
52. Li Y, Tian Y, Yu C, et al. A systematic review and meta-Analysis of antiadhesion molecule therapy in patients with active Crohn?s disease. Scand J Gastroenterol. 2009;44:1435-1442.
53. Danese S, Sans M, de la Motte C, et al. Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology. 2006;130:2060-2073.
54. Hatoum OA, Heidemann J, Binion DG. The intestinal microvasculature as a therapeutic target in inflammatory bowel disease. Ann N Y Acad Sci. 2006;1072:78-97.
55. Azzam N. Angiogenesis and inflammatory bowel disease. Saudi J Gastroenterol. 2007;13:37-38.
56. Hatoum OA, Binion DG. The vasculature and inflammatory bowel disease: contribution to pathogenesis and clinical pathology. Inflamm Bowel Dis. 2005;11:304-313.
57. Danese S, Scaldaferri F, Vetrano S, et al. Critical role of the CD40 CD40-ligand pathway in regulating mucosal inflammation-driven angiogenesis in inflammatory bowel disease. Gut. 2007;56:1248-1256.
58. Koutroubakis IE, Tsiolakidou G, Karmiris K, et al. Role of angiogenesis in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12:515-523.
59. Maconi G, Sampietro GM, Russo A, et al. The vascularity of internal fistulae in Crohn?s disease: an in vivo power doppler ultrasonography assessment. Gut. 2002;50:496-500.
60. Spalinger J, Patriquin H, Miron MC, et al. Doppler US in patients with crohn disease: vessel density in the diseased bowel reflects disease activity. Radiology. 2000;217:787-791.
61. Brahme F, Lindstrom C. A comparative radiographic and pathological study of intestinal vaso-Architecture in Crohn?s disease and in ulcerative colitis. Gut. 1970;11:928-940.
62. Scott EM, Freeman AH. Prominent omental and mesenteric vasculature in inflammatory bowel disease shown by computed tomography. Eur J Radiol. 1996;22:104-106.
63. Danese S, Fiorino G, Angelucci E, et al. Narrow-band imaging endoscopy to assess mucosal angiogenesis in inflammatory bowel disease: a pilot study. World J Gastroenterol. 2010;16:2396-2400.
64. Deban L, Correale C, Vetrano S, et al. Multiple pathogenic roles of microvasculature in inflammatory bowel disease: a Jack of all trades. Am J Pathol. 2008;172:1457-1466.
65. Hatoum OA, Binion DG, Otterson MF, et al. Acquired microvascular dysfunction in inflammatory bowel disease: loss of nitric oxide-mediated vasodilation. Gastroenterology. 2003;125:58-69.
66. Lebuffe G, Haddad E, Desreumaux P, et al. Impaired contractile response of mesenteric arteries in Crohn?s disease. Aliment Pharmacol Ther. 2000;14:1279-1285.
67. Chidlow JH Jr, Langston W, Greer JJ, et al. Differential angiogenic regulation of experimental colitis. Am J Pathol. 2006;169: 2014-2030.
68. Kanazawa S, Tsunoda T, Onuma E, et al. VEGF, basic-FGF, and TGFbeta in Crohn?s disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation. Am J Gastroenterol. 2001;96:822-828.
69. Ferrante M, Pierik M, Henckaerts L, et al. The role of vascular endothelial growth factor (VEGF) in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12:870-878.
70. Kapsoritakis A, Sfiridaki A, Maltezos E, et al. Vascular endothelial growth factor in inflammatory bowel disease. Int J Colorectal Dis. 2003;18:418-422.
71. Griga T, Gutzeit A, Sommerkamp C, et al. Increased production of vascular endothelial growth factor by peripheral blood mononuclear cells in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 1999;11:175-179.
72. Chidlow JH Jr, Shukla D, Grisham MB, et al. Pathogenic angiogenesis in IBD and experimental colitis: new ideas and therapeutic avenues. Am J Physiol Gastrointest Liver Physiol. 2007;293:G5-G18.
73. Pousa ID, Mate J, Salcedo-Mora X, et al. Role of vascular endothelial growth factor and angiopoietin systems in serum of Crohn?s disease patients. Inflamm Bowel Dis. 2008;14:61-67.
74. Oikonomou KA, Kapsoritakis AN, Kapsoritaki AI, et al. Angiogenin, angiopoietin-1, angiopoietin-2, and endostatin serum levels in inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:963-970.
75. Vainer B, Nielsen OH, Horn T. Comparative studies of the colonic in situ expression of intercellular adhesion molecules (ICAM-1,-2, and-3), beta2 integrins (LFA-1, Mac-1, and p150, 95), and PECAM-1 in ulcerative colitis and Crohn?s disease. Am J Surg Pathol. 2000;24: 1115-1124.
76. Goto A, Arimura Y, Shinomura Y, et al. Antisense therapy of MAdCAM-1 for trinitrobenzenesulfonic acid-induced murine colitis. Inflamm Bowel Dis. 2006;12:758-765.
77. Soriano A, Salas A, Sans M, et al. VCAM-1, but not ICAM-1 or MAdCAM-1, immunoblockade ameliorates DSS-induced colitis in mice. Lab Invest. 2000;80:1541-1551.
78. Burns RC, Rivera-Nieves J, Moskaluk CA, et al. Antibody blockade of ICAM-1 and VCAM-1 ameliorates inflammation in the SAMP-1/Yit adoptive transfer model of Crohn?s disease in mice. Gastroenterology. 2001;121:1428-1436.
79. Hamamoto N, Maemura K, Hirata I, et al. Inhibition of dextran sulphate sodium (DSS)-induced colitis in mice by intracolonically administered antibodies against adhesion molecules (endothelial leucocyte adhesion molecule-1 (ELAM-1) or intercellular adhesion molecule-1 (ICAM-1)). Clin Exp Immunol. 1999;117:462-468.
80. Bendjelloul F, Maly P, Mandys V, et al. Intercellular adhesion molecule-1 (ICAM-1) deficiency protects mice against severe forms of experimentally induced colitis. Clin Exp Immunol. 2000;119:57-63.
81. McLaren WJ, Anikijenko P, Thomas SG, et al. In vivo detection of morphological and microvascular changes of the colon in association with colitis using fiberoptic confocal imaging (FOCI). Dig Dis Sci. 2002;47:2424-2433.
82. Funayama Y, Sasaki I, Naito H, et al. Remodeling of vascular wall in Crohn?s disease. Dig Dis Sci. 1999;44:2319-2323.
83. Costa C, Incio J, Soares R. Angiogenesis and chronic inflammation: cause or consequence?. Angiogenesis. 2007;10:149-166.
84. Saito S, Tsuno NH, Sunami E, et al. Expression of platelet-derived endothelial cell growth factor in inflammatory bowel disease. J Gastroenterol. 2003;38:229-237.
85. Bousvaros A, Leichtner A, Zurakowski D, et al. Elevated serum vascular endothelial growth factor in children and young adults with Crohn?s disease. Dig Dis Sci. 1999;44:424-430.
86. Di Sabatino A, Ciccocioppo R, Armellini E, et al. Serum bFGF and VEGF correlate respectively with bowel wall thickness and intramural blood flow in Crohn?s disease. Inflamm Bowel Dis. 2004;10:573-577.
87. Rutella S, Fiorino G, Vetrano S, et al. Infliximab therapy inhibits inflammation-induced angiogenesis in the mucosa of patients with Crohn?s disease. Am J Gastroenterol. 2011;106:762-770.
88. Algaba A, Linares PM, Encarnacion Fernandez-Contreras M, et al. The effects of infliximab or adalimumab on vascular endothelial growth factor and angiopoietin 1 angiogenic factor levels in inflammatory bowel disease: serial observations in 37 patients. Inflamm Bowel Dis. 2014;20: 695-702.
89. Lee SS, Ha HK, Yang SK, et al. CT of prominent pericolic or perienteric vasculature in patients with Crohn?s disease: correlation with clinical disease activity and findings on barium studies. AJR Am J Roentgenol. 2002;179:1029-1036.
90. Maconi G, Imbesi V, Bianchi Porro G. Doppler ultrasound measurement of intestinal blood flow in inflammatory bowel disease. Scand J Gastroenterol. 1996;31:590-593.
91. van Oostayen JA, Wasser MN, van Hogezand RA, et al. Doppler sonography evaluation of superior mesenteric artery flow to assess Crohn?s disease activity: correlation with clinical evaluation, Crohn?s disease activity index, and alpha 1-Antitrypsin clearance in feces. AJR Am J Roentgenol. 1997;168:429-433.
92. van Oostayen JA, Wasser MN, Griffioen G, et al. Diagnosis of Crohn?s ileitis and monitoring of disease activity: value of doppler ultrasound of superior mesenteric artery flow. Am J Gastroenterol. 1998;93:88-91.
93. Bolondi L, Gaiani S, Brignola C, et al. Changes in splanchnic hemodynamics in inflammatory bowel disease. Non-invasive assessment by doppler ultrasound flowmetry. Scand J Gastroenterol. 1992;27: 501-507.
94. Kircher PR, Spaulding KA, Vaden S, et al. Doppler ultrasonographic evaluation of gastrointestinal hemodynamics in food hypersensitivities: a canine model. J Vet Intern Med. 2004;18:605-611.
95. Erikson U, Fagerberg S, Krause U, et al. Angiographic studies in Crohn?s disease and ulcerative colitis. Am J Roentgenol Radium Ther Nucl Med. 1970;110:385-392.
96. Brahme F. Mesenteric angiography in regional enterocolitis. Radiology. 1966;87:1037-1042.
97. Ludwig D, Wiener S, Bruning A, et al. Mesenteric blood flow is related to disease activity and risk of relapse in Crohn?s disease: a prospective follow-up study. Am J Gastroenterol. 1999;94:2942-2950.
98. Park MJ, Lim JS. Computed tomography enterography for evaluation of inflammatory bowel disease. Clin Endosc. 2013;46:327-366.
99. Meyers MA, McGuire PV. Spiral CT demonstration of hypervascularity in Crohn disease: vascular jejunization of the ileum? or the ?comb sign?. Abdom Imaging. 1995;20:327-332.
100. Miehsler W, Reinisch W, Valic E, et al. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism?. Gut. 2004;53:542-548.
101. Spina L, Saibeni S, Battaglioli T, et al. Thrombosis in inflammatory bowel diseases: role of inherited thrombophilia. Am J Gastroenterol. 2005;100:2036-2041.
102. Jackson CS, Fryer J, Danese S, et al. Mesenteric vascular thromboembolism in inflammatory bowel disease: a single center experience. J Gastrointest Surg. 2011;15:97-100.
103. Vietti Violi N, Schoepfer AM, Fournier N, et al. Prevalence and clinical importance of mesenteric venous thrombosis in the Swiss inflammatory bowel disease Cohort. AJR Am J Roentgenol. 2014;203:62-69.
104. Hatoum OA, Spinelli KS, Abu-Hajir M, et al. Mesenteric venous thrombosis in inflammatory bowel disease. J Clin Gastroenterol. 2005;39:27-31.
105. Collins CE, Rampton DS, Rogers J, et al. Platelet aggregation and neutrophil sequestration in the mesenteric circulation in inflammatory bowel disease. Eur J Gastroenterol Hepatol. 1997;9:1213-1217.
106. Fagerstam JP, Whiss PA. Higher platelet P-selectin in male patients with inflammatory bowel disease compared to healthy males. World J Gastroenterol. 2006;12:1270-1272.
107. Andoh A, Yoshida T, Yagi Y, et al. Increased aggregation response of platelets in patients with inflammatory bowel disease. J Gastroenterol. 2006;41:47-54.
108. Lanzarotto F, Carpani M, Chaudhary R, et al. Novel treatment options for inflammatory bowel disease: targeting alpha 4 integrin. Drugs. 2006; 66:1179-1189.
109. Van Assche G, Rutgeerts P. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases. I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol. 2005;288: G169-G174.
110. van Assche G, Rutgeerts P. Antiadhesion molecule therapy in inflammatory bowel disease. Inflamm Bowel Dis. 2002;8:291-300.
111. Ghosh S, Panaccione R. Anti-Adhesion molecule therapy for inflammatory bowel disease. Therap Adv Gastroenterol. 2010;3:239-258.
112. Gordon FH, Lai CW, Hamilton MI, et al. A randomized placebocontrolled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn?s disease. Gastroenterology. 2001;121:268-274.
113. Feagan BG, Greenberg GR, Wild G, et al. Treatment of active Crohn?s disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol. 2008;6:1370-1377.
114. Yacyshyn BR, Chey WY, Goff J, et al. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn?s disease. Gut. 2002;51:30-36.
115. Schmid-Schonbein GW. Microlymphatics and lymph flow. Physiol Rev. 1990;70:987-1028.
116. Skalak TC, Schmid-Schonbein GW, Zweifach BW. New morphological evidence for a mechanism of lymph formation in skeletal muscle. Microvasc Res. 1984;28:95-112.
117. Negrini D, Moriondo A. Lymphatic anatomy and biomechanics. J Physiol. 2011;589:2927-2934.
118. Nakamura K, Rockson SG. Biomarkers of lymphatic function and disease: state of the art and future directions. Mol Diagn Ther. 2007;11: 227-238.
119. von der Weid PY, Zawieja DC. Lymphatic smooth muscle: the motor unit of lymph drainage. Int J Biochem Cell Biol. 2004;36:1147-1153.
120. Deitch EA. Gut lymph and lymphatics: a source of factors leading to organ injury and dysfunction. Ann N Y Acad Sci. 2010;1207(suppl 1): E103-E111.
121. Dongaonkar RM, Nguyen TL, Quick CM, et al. Adaptation of mesenteric lymphatic vessels to prolonged changes in transmural pressure. Am J Physiol Heart Circ Physiol. 2013;305:H203-H210.
122. Miller MJ, McDole JR, Newberry RD. Microanatomy of the intestinal lymphatic system. Ann N Y Acad Sci. 2010;1207(suppl 1):E21-E28.
123. Liao S, Cheng G, Conner DA, et al. Impaired lymphatic contraction associated with immunosuppression. Proc Natl Acad Sci U S A. 2011; 108:18784-18789.
124. Kvietys PR, Granger DN. Role of intestinal lymphatics in interstitial volume regulation and transmucosal water transport. Ann N Y Acad Sci. 2010;1207(suppl 1):E29-E43.
125. von der Weid PY, Rehal S, Ferraz JG. Role of the lymphatic system in the pathogenesis of Crohn?s disease. Curr Opin Gastroenterol. 2011;27: 335-341.
126. Alexander JS, Chaitanya GV, Grisham MB, et al. Emerging roles of lymphatics in inflammatory bowel disease. Ann N Y Acad Sci. 2010; 1207(suppl 1):E75-E85.
127. Rockson SG. Causes and consequences of lymphatic disease. Ann N Y Acad Sci. 2010;1207(suppl 1):E2-E6.
128. Wu TF, MacNaughton WK, von der Weid PY. Lymphatic vessel contractile activity and intestinal inflammation. Mem Inst Oswaldo Cruz. 2005;100(suppl 1):107-110.
129. Kohan A, Yoder S, Tso P. Lymphatics in intestinal transport of nutrients and gastrointestinal hormones. Ann N Y Acad Sci. 2010;1207(Suppl 1): E44-E51.
130. Alexander JS, Ganta VC, Jordan PA, et al. Gastrointestinal lymphatics in health and disease. Pathophysiology. 2010;17:315-335.
131. Heatley RV, Bolton PM, Hughes LE, et al. Mesenteric lymphatic obstruction in Crohn?s disease. Digestion. 1980;20:307-313.
132. Van Kruiningen HJ, Colombel JF. The forgotten role of lymphangitis in Crohn?s disease. Gut. 2008;57:1-4.
133. Behr MA. The path to Crohn?s disease: is mucosal pathology a secondary event?. Inflamm Bowel Dis. 2010;16:896-902.
134. Liao S, Ruddle NH. Synchrony of high endothelial venules and lymphatic vessels revealed by immunization. J Immunol. 2006;177: 3369-3379.
135. Angeli V, Ginhoux F, Llodra J, et al. B cell-driven lymphangiogenesis in inflamed lymph nodes enhances dendritic cell mobilization. Immunity. 2006;24:203-215.
136. Chakraborty S, Zawieja S, Wang W, et al. Lymphatic system: a vital link between metabolic syndrome and inflammation. Ann N Y Acad Sci. 2010;1207(suppl 1):E94-E102.
137. Dixon JB. Lymphatic lipid transport: sewer or subway?. Trends Endocrinol Metab. 2010;21:480-487.
138. Von Der Weid PY, Rehal S. Lymphatic pump function in the inflamed gut. Ann N Y Acad Sci. 2010;1207(suppl 1):E69-E74.
139. Kalima TV, Saloniemi H, Rahko T. Experimental regional enteritis in pigs. Scand J Gastroenterol. 1976;11:353-362.
140. Reichert FL, Mathes ME. Experimental lymphedema of the intestinal tract and its relation to regional Cicatrizing enteritis. Ann Surg. 1936; 104:601-616.
141. Wu TF, Carati CJ, Macnaughton WK, et al. Contractile activity of lymphatic vessels is altered in the TNBS model of guinea pig ileitis. Am J Physiol Gastrointest Liver Physiol. 2006;291:G566-G574.
142. Honkonen KM, Visuri MT, Tervala TV, et al. Lymph node transfer and perinodal lymphatic growth factor treatment for lymphedema. Ann Surg. 2013;257:961-967.
143. Jurisic G, Sundberg JP, Detmar M. Blockade of VEGF receptor-3 aggravates inflammatory bowel disease and lymphatic vessel enlargement. Inflamm Bowel Dis. 2013;19:1983-1989.
144. D?Alessio S, Correale C, Tacconi C, et al. VEGF-C-dependent stimulation of lymphatic function ameliorates experimental inflammatory bowel disease. J Clin Invest. 2014;124:3863-3878.
145. Harvey NL, Srinivasan RS, Dillard ME, et al. Lymphatic vascular defects promoted by Prox1 haploinsufficiency cause adult-onset obesity. Nat Genet. 2005;37:1072-1081.
146. von der Weid PY, Rainey KJ. Review article: lymphatic system and associated adipose tissue in the development of inflammatory bowel disease. Aliment Pharmacol Ther. 2010;32:697-711.
147. Desreumaux P, Ernst O, Geboes K, et al. Inflammatory alterations in mesenteric adipose tissue in Crohn?s disease. Gastroenterology. 1999; 117:73-81.
148. Lim HY, Rutkowski JM, Helft J, et al. Hypercholesterolemic mice exhibit lymphatic vessel dysfunction and degeneration. Am J Pathol. 2009;175:1328-1337.
149. Robb-Smith AH. A bird?s-eye view of Crohn?s disease. Proc R Soc Med. 1971;64:157-161.
150. Sura R, Colombel JF, Van Kruiningen HJ. Lymphatics, tertiary lymphoid organs and the granulomas of Crohn?s disease: an immunohistochemical study. Aliment Pharmacol Ther. 2011;33:930-939.
151. Kovi J, Duong HD, Hoang CT. Ultrastructure of intestinal lymphatics in Crohn?s disease. Am J Clin Pathol. 1981;76:385-394.
152. Cullen G, O?Toole A, Keegan D, et al. Long-Term clinical results of ileocecal resection for Crohn?s disease. Inflamm Bowel Dis. 2007;13: 1369-1373.
153. Simillis C, Jacovides M, Reese GE, et al. Meta-Analysis of the role of granulomas in the recurrence of Crohn disease. Dis Colon Rectum. 2010; 53:177-185.
154. Denoya P, Canedo J, Berho M, et al. Granulomas in Crohn?s disease: does progression through the bowel layers affect presentation or predict recurrence?. Colorectal Dis. 2011;13:1142-1147.
155. Tonelli F, Ficari F. Pathological features of Crohn?s disease determining perforation. J Clin Gastroenterol. 1991;13:226-230.
156. Cook MG, Dixon MF. An analysis of the reliability of detection and diagnostic value of various pathological features in Crohn?s disease and ulcerative colitis. Gut. 1973;14:255-262.
157. Shelley-Fraser G, Borley NR, Warren BF, et al. The connective tissue changes of Crohn?s disease. Histopathology. 2012;60:1034-1044.
158. Rahier JF, De Beauce S, Dubuquoy L, et al. Increased lymphatic vessel density and lymphangiogenesis in inflammatory bowel disease. Aliment Pharmacol Ther. 2011;34:533-543.
159. Pedica F, Ligorio C, Tonelli P, et al. Lymphangiogenesis in Crohn?s disease: an immunohistochemical study using monoclonal antibody D2-40. Virchows Arch. 2008;452:57-63.
160. Geleff S, Schoppmann SF, Oberhuber G. Increase in podoplaninexpressing intestinal lymphatic vessels in inflammatory bowel disease. Virchows Arch. 2003;442:231-237.
161. Rahier JF, Dubuquoy L, Colombel JF, et al. Decreased lymphatic vessel density is associated with postoperative endoscopic recurrence in Crohn?s disease. Inflamm Bowel Dis. 2013;19:2084-2090.
162. Tonelli F, Giudici F, Liscia G. Is lymphatic status related to regression of inflammation in Crohn?s disease?. World J Gastrointest Surg. 2012;4: 228-233.
163. Van Kruiningen HJ, Hayes AW, Colombel JF. Granulomas obstruct lymphatics in all layers of the intestine in Crohn?s disease. APMIS. 2014;122:1125-1129.
164. Li Y, Stocchi L, Liu X, et al. Presence of granulomas in mesenteric lymph nodes is associated with postoperative recurrence in Crohn?s disease. Inflamm Bowel Dis. 2015;21:2613-2618.
165. Schaffler A, Scholmerich J. Innate immunity and adipose tissue biology. Trends Immunol. 2010;31:228-235.
166. Batra A, Pietsch J, Fedke I, et al. Leptin-dependent toll-like receptor expression and responsiveness in preadipocytes and adipocytes. Am J Pathol. 2007;170:1931-1941.
167. Stroh T, Batra A, Glauben R, et al. Nucleotide oligomerization domains 1 and 2: regulation of expression and function in preadipocytes. J Immunol. 2008;181:3620-3627.
168. Schaffler A, Herfarth H. Creeping fat in Crohn?s disease: travelling in a creeper lane of research?. Gut. 2005;54:742-744.
169. Siegmund B. Mesenteric fat in Crohn?s disease: the hot spot of inflammation?. Gut. 2012;61:3-5.
170. Karmiris K, Koutroubakis IE, Kouroumalis EA. The emerging role of adipocytokines as inflammatory mediators in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:847-855.
171. Peyrin-Biroulet L, Gonzalez F, Dubuquoy L, et al. Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn?s disease. Gut. 2012;61:78-85.
172. Zulian A, Cancello R, Micheletto G, et al. Visceral adipocytes: old actors in obesity and new protagonists in Crohn?s disease?. Gut. 2012;61:86-94.
173. Drouet M, Dubuquoy L, Desreumaux P, et al. Visceral fat and gut inflammation. Nutrition. 2012;28:113-117.
174. Schaffler A, Scholmerich J, Buchler C. Mechanisms of disease: adipocytokines and visceral adipose tissue-emerging role in intestinal and mesenteric diseases. Nat Clin Pract Gastroenterol Hepatol. 2005; 2:103-111.
175. Schaffler A, Furst A, Buchler C, et al. Secretion of RANTES (CCL5) and interleukin-10 from mesenteric adipose tissue and from creeping fat in Crohn?s disease: regulation by steroid treatment. J Gastroenterol Hepatol. 2006;21:1412-1418.
176. Zulian A, Cancello R, Ruocco C, et al. Differences in visceral fat and fat bacterial colonization between ulcerative colitis and Crohn?s disease. An in vivo and in vitro study. PLoS One. 2013;8:e78495.
177. Erhayiem B, Dhingsa R, Hawkey CJ, et al. Ratio of visceral to subcutaneous fat area is a biomarker of complicated Crohn?s disease. Clin Gastroenterol Hepatol. 2011;9:684-687. e681.
178. Feng Y, Li Y, Mei S, et al. Exclusive enteral nutrition ameliorates mesenteric adipose tissue alterations in patients with active Crohn?s disease. Clin Nutr. 2014;33:850-858.
179. Li Y, Zhu W, Gong J, et al. Influence of exclusive enteral nutrition therapy on visceral fat in patients with Crohn?s disease. Inflamm Bowel Dis. 2014;20:1568-1574.
180. Maconi G, Greco S, Duca P, et al. Prevalence and clinical significance of sonographic evidence of mesenteric fat alterations in Crohn?s disease. Inflamm Bowel Dis. 2008;14:1555-1561.
181. Peyrin-Biroulet L, Chamaillard M, Gonzalez F, et al. Mesenteric fat in Crohn?s disease: a pathogenetic hallmark or an innocent bystander?. Gut. 2007;56:577-583.
182. Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab. 2000;11:327-332.
183. Ailhaud G. Adipose tissue as an endocrine organ. Int J Obes Relat Metab Disord. 2000;24(suppl 2):S1-S3.
184. Galic S, Oakhill JS, Steinberg GR. Adipose tissue as an endocrine organ. Mol Cell Endocrinol. 2010;316:129-139.
185. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89:2548-2556.
186. Breese EJ, Michie CA, Nicholls SW, et al. Tumor necrosis factor alphaproducing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology. 1994;106:1455-1466.
187. Zuo L, Li Y, Zhu W, et al. Mesenteric adipocyte dysfunction in Crohn?s disease is associated with hypoxia. Inflamm Bowel Dis. 2016;22:114-126.
188. de Oliveira CC, Acedo SC, Pedrazzoli J Jr, et al. Depot-specific alterations to insulin signaling in mesenteric adipose tissue during intestinal inflammatory response. Int Immunopharmacol. 2009;9:396-402.
189. Gambero A, Marostica M, Abdalla Saad MJ, et al. Mesenteric adipose tissue alterations resulting from experimental reactivated colitis. Inflamm Bowel Dis. 2007;13:1357-1364.
190. Paul G, Schaffler A, Neumeier M, et al. Profiling adipocytokine secretion from creeping fat in Crohn?s disease. Inflamm Bowel Dis. 2006; 12:471-477.
191. Shamir R. Nutritional aspects in inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2009;48(suppl 2):S86-S88.
192. Uko V, Vortia E, Achkar JP, et al. Impact of abdominal visceral adipose tissue on disease outcome in pediatric Crohn?s disease. Inflamm Bowel Dis. 2014;20:2286-2291.
193. Wiskin AE, Wootton SA, Hunt TM, et al. Body composition in childhood inflammatory bowel disease. Clin Nutr. 2011;30:112-115.
194. Colombel JF, Solem CA, Sandborn WJ, et al. Quantitative measurement and visual assessment of ileal Crohn?s disease activity by computed tomography enterography: correlation with endoscopic severity and C reactive protein. Gut. 2006;55:1561-1567.
195. Li Y, Zhu W, Gong J, et al. Visceral fat area is associated with a high risk for early postoperative recurrence in Crohn?s disease. Colorectal Dis. 2015;17:225-234.
196. Zhao D, Wu XR, Remer EM, et al. Association between high visceral fat area and postoperative complications in patients with Crohn?s disease following the primary surgery. Colorectal Dis. 2016;18:163-172.
197. Clemente TR, Dos Santos AN, Sturaro JN, et al. Infliximab modifies mesenteric adipose tissue alterations and intestinal inflammation in rats with TNBS-induced colitis. Scand J Gastroenterol. 2012;47:943-950.
198. Parmentier-Decrucq E, Duhamel A, Ernst O, et al. Effects of infliximab therapy on abdominal fat and metabolic profile in patients with Crohn?s disease. Inflamm Bowel Dis. 2009;15:1476-1484.
199. Thomaz MA, Acedo SC, de Oliveira CC, et al. Methotrexate is effective in reactivated colitis and reduces inflammatory alterations in mesenteric adipose tissue during intestinal inflammation. Pharmacol Res. 2009;60: 341-346.
200. Mencarelli A, Distrutti E, Renga B, et al. Probiotics modulate intestinal expression of nuclear receptor and provide counter-regulatory signals to inflammation-driven adipose tissue activation. PLoS One. 2011;6: e22978.
201. Horber FF, Zurcher RM, Herren H, et al. Altered body fat distribution in patients with glucocorticoid treatment and in patients on long-Term dialysis. Am J Clin Nutr. 1986;43:758-769.
202. Mauras N, George D, Evans J, et al. Growth hormone has anabolic effects in glucocorticosteroid-dependent children with inflammatory bowel disease: a pilot study. Metabolism. 2002;51:127-135.
203. Slonim AE, Bulone L, Damore MB, et al. A preliminary study of growth hormone therapy for Crohn?s disease. N Engl J Med. 2000; 342:1633-1637.
204. Li Y, Zuo L, Zhu W, et al. Telmisartan attenuates the inflamed mesenteric adipose tissue in spontaneous colitis by mechanisms involving regulation of neurotensin/microRNA-155 pathway. Biochem Pharmacol. 2015;93:461-469.
205. Fazio VW, Marchetti F, Church M, et al. Effect of resection margins on the recurrence of Crohn?s disease in the small bowel. A randomized controlled trial. Ann Surg. 1996;224:563-571; discussion 571-563.
206. Cooper JC, Williams NS. The influence of microscopic disease at the margin of resection on recurrence rates in Crohn?s disease. Ann R Coll Surg Engl. 1986;68:23-26.
207. Kim H, Kataru RP, Koh GY. Regulation and implications of inflammatory lymphangiogenesis. Trends Immunol. 2012;33:350-356.
208. de Fontgalland D, Brookes SJ, Gibbins I, et al. The neurochemical changes in the innervation of human colonic mesenteric and submucosal blood vessels in ulcerative colitis and Crohn?s disease. Neurogastroenterol Motil. 2014;26:731-744.
209. Harvey NL. The link between lymphatic function and adipose biology. Ann N Y Acad Sci. 2008;1131:82-88.
210. Alitalo K. The lymphatic vasculature in disease. Nat Med. 2011;17: 1371-1380.
211. Davis MJ, Lane MM, Davis AM, et al. Modulation of lymphatic muscle contractility by the neuropeptide substance P. Am J Physiol Heart Circ Physiol. 2008;295:H587-H597.
212. Chakraborty S, Nepiyushchikh Z, Davis MJ, et al. Substance P activates both contractile and inflammatory pathways in lymphatics through the neurokinin receptors NK1R and NK3R. Microcirculation. 2011;18:24-35.
213. Ryan TJ. Lymphatics and adipose tissue. Clin Dermatol. 1995;13: 493-498.
214. Gross K, Karagiannides I, Thomou T, et al. Substance P promotes expansion of human mesenteric preadipocytes through proliferative and antiapoptotic pathways. Am J Physiol Gastrointest Liver Physiol. 2009;296:G1012-G1019.